NCT06111885

Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention

Name: Clinical Trial NCT06111885
Creator: Insel Gruppe AG, University Hospital Bern
Keywords: Kidney Stone, Indapamide 2.5 MG, Phase 2, drug, clinical trial, Switzerland

Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention

Insel Gruppe AG, University Hospital Bern·Phase 2·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Kidney Stone
Drug/Device/Intervention: Indapamide 2.5 MG
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Insel Gruppe AG, University Hospital Bern
Location: Bern, Switzerland

Timeline & enrollment

Phase: Phase 2
Start date: Apr 01, 2024
End date: Jun 01, 2027
Enrollment: 99 participants

Primary outcome

Primary outcome component 1 - calcium oxalate supersaturation in urine,Primary outcome component 2 - calcium phosphate supersaturation in urine

Summary

The aim of this study is to test the efficacy of the two long-acting thiazide-like diuretics indapamide and chlorthalidone in reducing urine supersaturation for calcium oxalate and calcium phosphate compared to the short-acting thiazide diuretic hydrochlorothiazide for the prevention of calcium-containing kidney stones.

ICD-10 classifications

Kidney dialysisSmall kidney, unspecifiedDisorder of kidney and ureter, unspecifiedInjury of kidneyUnspecified kidney failure

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06111885
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06111885 through Pure Global AI's free database. This Phase 2 trial is sponsored by Insel Gruppe AG, University Hospital Bern and is currently Not yet recruiting. The study focuses on Kidney Stone. Target enrollment is 99 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.